Publicaciones (43) Publicaciones en las que ha participado algún/a investigador/a

2011

  1. A new rapid desensitization protocol for chemotherapy agents

    Journal of Investigational Allergology and Clinical Immunology, Vol. 21, Núm. 2, pp. 108-112

  2. A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation

    Oncology Letters, Vol. 2, Núm. 5, pp. 807-809

  3. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: Can we trust the findings?

    Diseases of the Colon and Rectum, Vol. 54, Núm. 9, pp. 1141-1146

  4. Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: A phase II study

    Investigational New Drugs, Vol. 29, Núm. 6, pp. 1459-1464

  5. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  6. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

  7. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  8. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation

    European Respiratory Journal, Vol. 37, Núm. 3, pp. 624-631

  9. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  10. Current management of uterine sarcomas

    Clinical and Translational Oncology, Vol. 13, Núm. 5, pp. 307-314

  11. Cáncer epitelial de ovario: Tratamiento médico de los estadios I y II

    Revisiones en Cancer, Vol. 25, Núm. 1, pp. 40-45

  12. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  13. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB)

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4

  14. Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam radiotherapy

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4

  15. Direct effects of type I interferons on cells of the immune system

    Clinical Cancer Research, Vol. 17, Núm. 9, pp. 2619-2627

  16. Evaluation of multiple serum markers in advanced melanoma.

    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, Vol. 32, Núm. 6, pp. 1155-1161

  17. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients A GEICO study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 6, pp. 1048-1055

  18. Giant cell tumors of the sacrum treated with intralesional resection and radiotherapy: A case series and review of the literature

    European Orthopaedics and Traumatology, Vol. 1, Núm. 5, pp. 175-179

  19. Identificación de las vías de drenaje linfático y biopsia selectiva de ganglio centinela en un paciente con melanoma amelanocítico de úvula

    Revista Espanola de Medicina Nuclear, Vol. 30, Núm. 5, pp. 325-326

  20. Identificación de las vías de drenaje linfático y biopsia selectiva de ganglio centinela en un paciente con melanoma amelanocítico de úvula

    Revista española de medicina nuclear, Vol. 30, Núm. 5, pp. 325-326